1. Medtech Insight
  2. >>Device Area
  3. >>Oncology

Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test

Test Targets Unmet Need For GERD Patients At Risk Of Developing Precancer And Cancer

 
• By Ashley Yeo

Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.

Esophageal Cancer vector
• Source: Shutterstock

In over three decades in medicine, Lishan Aklog has experienced breakthrough moments as a heart surgeon in the US, UK and France, and since 2018, as chair and CEO ofLucid Diagnostics, Inc., which is a subsidiary of PAVmed Inc..

But potentially the biggest moment is yet to arrive: Lucid Diagnostics will hold a pre-submission meeting with Medicare’s MolDX program in the coming weeks in a bid for reimbursement

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

More from Device Area

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By Marion Webb

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.

FDA Announces Classifications On 9 Device Types

 
• By Elizabeth Orr

The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.